As of Feb 23
| +0.74 / +1.07%|
The 7 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 56.00, with a high estimate of 75.00 and a low estimate of 50.00. The median estimate represents a -19.99% decrease from the last price of 69.99.
The current consensus among 9 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.